Overview
AnaptysBio Q2 collaboration revenue more than doubles year-over-year
Net loss narrows to $38.6 mln from $46.7 mln in prior year
Co repurchased 9.3% of shares, reflecting confidence in financial position
Result Drivers
ROSNILIMAB DATA - Positive Phase 2b trial results for rosnilimab in rheumatoid arthritis with strong safety and efficacy profile
ULCERATIVE COLITIS TRIAL - Completed enrollment for Phase 2 trial with top-line data expected in Q4 2025
PIPELINE ADVANCEMENT - Ongoing Phase 1 trials for ANB033 and ANB101, with plans for a Phase 1b cohort for ANB033 in celiac disease
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Collaboration Revenue | $22.26 mln | ||
Q2 EPS | -$1.34 | ||
Q2 Net Income | -$38.63 mln | ||
Q2 Income From Operations | -$26.17 mln | ||
Q2 Operating Expenses | $48.43 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AnaptysBio Inc is $45.50, about 47.9% above its August 5 closing price of $23.69
Press Release: ID:nGNX8G2DQs
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。